Cargando…

Adjuvant gemcitabine and concurrent radiation for patients with resected pancreatic cancer: a phase II study

The safety and efficacy of gemcitabine and concurrent radiation to the upper abdomen followed by weekly gemcitabine in patients with resected pancreatic cancer was determined. Patients with resected adenocarcinoma of the pancreas were treated with intravenous gemcitabine administered twice-weekly (4...

Descripción completa

Detalles Bibliográficos
Autores principales: Blackstock, A W, Mornex, F, Partensky, C, Descos, L, Case, L D, Melin, S A, Levine, E A, Mishra, G, Limentani, S A, Kachnic, L A, Tepper, J E
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2006
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2360633/
https://www.ncbi.nlm.nih.gov/pubmed/16868545
http://dx.doi.org/10.1038/sj.bjc.6603270
_version_ 1782153097435414528
author Blackstock, A W
Mornex, F
Partensky, C
Descos, L
Case, L D
Melin, S A
Levine, E A
Mishra, G
Limentani, S A
Kachnic, L A
Tepper, J E
author_facet Blackstock, A W
Mornex, F
Partensky, C
Descos, L
Case, L D
Melin, S A
Levine, E A
Mishra, G
Limentani, S A
Kachnic, L A
Tepper, J E
author_sort Blackstock, A W
collection PubMed
description The safety and efficacy of gemcitabine and concurrent radiation to the upper abdomen followed by weekly gemcitabine in patients with resected pancreatic cancer was determined. Patients with resected adenocarcinoma of the pancreas were treated with intravenous gemcitabine administered twice-weekly (40 mg m(−2)) for 5 weeks concurrent with upper abdominal radiation (50.4 Gy in 5½ weeks). At the completion of the chemoradiation, patients without disease progression were given gemcitabine (1000 mg m(−2)) weekly for two cycles. Each cycle consisted of 3 weeks of treatment followed by 1 week without treatment. Forty-seven patients were entered, 46 of whom are included in this analysis. Characteristics: median age 61 years (range 35–79); 24 females (58%); 73% stage T3/T4; and 70% lymph node positive. Grade III/IV gastrointestinal or haematologic toxicities were infrequent. The median survival was 18.3 months, while the median time to disease recurrence was 10.3 months. Twenty-four percent of patients were alive at 3 years. Only six of 34 patients with progression experienced local regional relapse as a component of the first site of failure. These results confirm the feasibility of delivering adjuvant concurrent gemcitabine and radiation to the upper abdomen. This strategy produced good local regional tumour control.
format Text
id pubmed-2360633
institution National Center for Biotechnology Information
language English
publishDate 2006
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-23606332009-09-10 Adjuvant gemcitabine and concurrent radiation for patients with resected pancreatic cancer: a phase II study Blackstock, A W Mornex, F Partensky, C Descos, L Case, L D Melin, S A Levine, E A Mishra, G Limentani, S A Kachnic, L A Tepper, J E Br J Cancer Clinical Study The safety and efficacy of gemcitabine and concurrent radiation to the upper abdomen followed by weekly gemcitabine in patients with resected pancreatic cancer was determined. Patients with resected adenocarcinoma of the pancreas were treated with intravenous gemcitabine administered twice-weekly (40 mg m(−2)) for 5 weeks concurrent with upper abdominal radiation (50.4 Gy in 5½ weeks). At the completion of the chemoradiation, patients without disease progression were given gemcitabine (1000 mg m(−2)) weekly for two cycles. Each cycle consisted of 3 weeks of treatment followed by 1 week without treatment. Forty-seven patients were entered, 46 of whom are included in this analysis. Characteristics: median age 61 years (range 35–79); 24 females (58%); 73% stage T3/T4; and 70% lymph node positive. Grade III/IV gastrointestinal or haematologic toxicities were infrequent. The median survival was 18.3 months, while the median time to disease recurrence was 10.3 months. Twenty-four percent of patients were alive at 3 years. Only six of 34 patients with progression experienced local regional relapse as a component of the first site of failure. These results confirm the feasibility of delivering adjuvant concurrent gemcitabine and radiation to the upper abdomen. This strategy produced good local regional tumour control. Nature Publishing Group 2006-08-07 2006-07-25 /pmc/articles/PMC2360633/ /pubmed/16868545 http://dx.doi.org/10.1038/sj.bjc.6603270 Text en Copyright © 2006 Cancer Research UK https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material.If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/.
spellingShingle Clinical Study
Blackstock, A W
Mornex, F
Partensky, C
Descos, L
Case, L D
Melin, S A
Levine, E A
Mishra, G
Limentani, S A
Kachnic, L A
Tepper, J E
Adjuvant gemcitabine and concurrent radiation for patients with resected pancreatic cancer: a phase II study
title Adjuvant gemcitabine and concurrent radiation for patients with resected pancreatic cancer: a phase II study
title_full Adjuvant gemcitabine and concurrent radiation for patients with resected pancreatic cancer: a phase II study
title_fullStr Adjuvant gemcitabine and concurrent radiation for patients with resected pancreatic cancer: a phase II study
title_full_unstemmed Adjuvant gemcitabine and concurrent radiation for patients with resected pancreatic cancer: a phase II study
title_short Adjuvant gemcitabine and concurrent radiation for patients with resected pancreatic cancer: a phase II study
title_sort adjuvant gemcitabine and concurrent radiation for patients with resected pancreatic cancer: a phase ii study
topic Clinical Study
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2360633/
https://www.ncbi.nlm.nih.gov/pubmed/16868545
http://dx.doi.org/10.1038/sj.bjc.6603270
work_keys_str_mv AT blackstockaw adjuvantgemcitabineandconcurrentradiationforpatientswithresectedpancreaticcanceraphaseiistudy
AT mornexf adjuvantgemcitabineandconcurrentradiationforpatientswithresectedpancreaticcanceraphaseiistudy
AT partenskyc adjuvantgemcitabineandconcurrentradiationforpatientswithresectedpancreaticcanceraphaseiistudy
AT descosl adjuvantgemcitabineandconcurrentradiationforpatientswithresectedpancreaticcanceraphaseiistudy
AT caseld adjuvantgemcitabineandconcurrentradiationforpatientswithresectedpancreaticcanceraphaseiistudy
AT melinsa adjuvantgemcitabineandconcurrentradiationforpatientswithresectedpancreaticcanceraphaseiistudy
AT levineea adjuvantgemcitabineandconcurrentradiationforpatientswithresectedpancreaticcanceraphaseiistudy
AT mishrag adjuvantgemcitabineandconcurrentradiationforpatientswithresectedpancreaticcanceraphaseiistudy
AT limentanisa adjuvantgemcitabineandconcurrentradiationforpatientswithresectedpancreaticcanceraphaseiistudy
AT kachnicla adjuvantgemcitabineandconcurrentradiationforpatientswithresectedpancreaticcanceraphaseiistudy
AT tepperje adjuvantgemcitabineandconcurrentradiationforpatientswithresectedpancreaticcanceraphaseiistudy